Works matching DE "AFATINIB"

Results: 187
    1

    Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers.

    Published in:
    Cancers, 2025, v. 17, n. 11, p. 1830, doi. 10.3390/cancers17111830
    By:
    • King, Gentry G.;
    • Baker, Kelsey K.;
    • Coveler, Andrew L.;
    • Harris, William P.;
    • Cohen, Stacey A.;
    • Shankaran, Veena;
    • Zhen, David B.;
    • Safyan, Rachael A.;
    • Lee, Hannah H.;
    • Alidina, Annie;
    • Hensel, Jeniece;
    • Hibbert, Reina;
    • Durm, Greg A.;
    • LaFary, Yvonne C.;
    • Younger, Anne;
    • Kugel, Sita;
    • Collisson, Eric;
    • Konnick, Eric Q.;
    • Redman, Mary W.;
    • Schneider, Bryan P.
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif<sup>®</sup> in healthy Chinese subjects.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 6, p. 2585, doi. 10.1007/s00432-022-04148-1
    By:
    • Liu, Guangwen;
    • Xue, Jinling;
    • Wang, Yanli;
    • Liu, Zhengzhi;
    • Li, Xue;
    • Qu, Dongmei;
    • Su, Zhengjie;
    • Xu, Kaibo;
    • Qu, Xinyao;
    • Qu, Zhaojuan;
    • Sun, Linlin;
    • Cao, Mingming;
    • Wang, Ying;
    • Chen, Xuesong;
    • Yu, Jing;
    • Liu, Lang;
    • Deng, Qiaohuan;
    • Zhao, Yicheng;
    • Zhang, Lixiu;
    • Yang, Haimiao
    Publication type:
    Article
    25

    Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 2, p. 865, doi. 10.1007/s00432-022-03984-5
    By:
    • Gursoy, Pınar;
    • Tatli, Ali Murat;
    • Erdem, Dilek;
    • Goker, Erdem;
    • Celik, Emir;
    • Demirci, Nebi Serkan;
    • Sakin, Abdullah;
    • Atci, Muhammed Mustafa;
    • Bayram, Ertuğrul;
    • Telli, Tuğba Akın;
    • Bilgin, Burak;
    • Bilici, Ahmet;
    • Akangunduz, Baran;
    • Balli, Sevinç;
    • Demirkazik, Ahmet;
    • Selçukbiricik, Fatih;
    • Menekse, Serkan;
    • Cavdar, Eyyüp;
    • Ozturk, Akın;
    • Bekmez, Esma Türkmen
    Publication type:
    Article
    26
    27

    Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 7, p. 2145, doi. 10.1007/s00432-020-03501-6
    By:
    • Bilgin, Burak;
    • Sendur, Mehmet Ali Nahit;
    • Yucel, Sebnem;
    • Celik, Emir;
    • Ozyukseler, Deniz Tataroglu;
    • Ayhan, Murat;
    • Basoglu, Tugba;
    • Ilhan, Aysegul;
    • Akdeniz, Nadiye;
    • Gulmez, Ahmet;
    • Dogan, Izzet;
    • Aktas, Burak Yasin;
    • Gurbuz, Mustafa;
    • Koca, Sinan;
    • Paydas, Semra;
    • Tatli, Ali Murat;
    • Cinkir, Havva Yesil;
    • Alan, Ozkan;
    • Erol, Cihan;
    • Hizal, Mutlu
    Publication type:
    Article
    28

    Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.

    Published in:
    Oncology & Therapy, 2022, v. 10, n. 1, p. 291, doi. 10.1007/s40487-022-00183-7
    By:
    • Baglivo, Sara;
    • Mandarano, Martina;
    • Bellezza, Guido;
    • Minotti, Vincenzo;
    • Bonaiti, Angelo;
    • Fischer, Matthias J.;
    • Birocchi, Ilaria;
    • Roila, Fausto;
    • Metelli, Niccolò;
    • Ludovini, Vienna;
    • Metro, Giulio
    Publication type:
    Article
    29
    30

    Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.

    Published in:
    Journal of Translational Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12967-022-03490-9
    By:
    • Bei, Roberto;
    • Benvenuto, Monica;
    • Focaccetti, Chiara;
    • Fazi, Sara;
    • Moretti, Marta;
    • Nardozi, Daniela;
    • Angiolini, Valentina;
    • Ciuffa, Sara;
    • Cifaldi, Loredana;
    • Carrano, Raffaele;
    • Palumbo, Camilla;
    • Miele, Martino Tony;
    • Bei, Riccardo;
    • Barillari, Giovanni;
    • Manzari, Vittorio;
    • De Smaele, Enrico;
    • Modesti, Andrea;
    • Masuelli, Laura
    Publication type:
    Article
    31
    32

    EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.

    Published in:
    Journal of Oncology Pharmacy Practice, 2023, v. 29, n. 4, p. 854, doi. 10.1177/10781552221085253
    By:
    • Delgado Sillero, Irene;
    • Lopetegui Lia, Nerea;
    • Sánchez Cousido, Luis Felipe;
    • Rojas Piedra, Mariam;
    • Távara Silva, Blanca;
    • Garrido Onecha, Maria Luisa;
    • Medina Valdivieso, Soledad;
    • Alonso Horcajo, Nieves;
    • Díez Tascón, Cristina;
    • López González, Ana;
    • Castañón López, Carmen;
    • Pedraza Lorenzo, Manuela;
    • García Palomo, Andrés;
    • Martín, Vicente;
    • Diz Tain, Pilar
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39

    Osimertinib 80 mg EOD? Does this work?

    Published in:
    Proceedings of Singapore Healthcare, 2022, v. 31, p. 1, doi. 10.1177/20101058221114743
    By:
    • Yik, Yeong Y;
    • A/L Alaga, Arvindran;
    • Hin, How S
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47

    A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2018, v. 82, n. 6, p. 1031, doi. 10.1007/s00280-018-3694-5
    By:
    • Oda, Naohiro;
    • Hotta, Kastuyuki;
    • Ninomiya, Kiichiro;
    • Minami, Daisuke;
    • Ichihara, Eiki;
    • Murakami, Toshi;
    • Yokoyama, Toshihide;
    • Ichikawa, Hirohisa;
    • Chikamori, Kenichi;
    • Takigawa, Nagio;
    • Ochi, Nobuaki;
    • Harita, Shingo;
    • Maeda, Yoshinobu;
    • Kiura, Katsuyuki
    Publication type:
    Article
    48
    49
    50